Exabis Library
Welcome to the e-CCO Library!
P436: Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P436: Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential application
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P436: Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P436: SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P437: Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapse
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P437: Confidence, acceptance, and friendship: the 3 winners at Camp Purple Live 2015
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P437: Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P437: Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn’s disease patients who have failed infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P437: Hyperbaric oxygen therapy for Inflammatory Bowel Disease – a systematic review
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P437: Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P437: Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P438: Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P438: Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extension
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P438: Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are rare but insidious adverse events: data from a large single-centre cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P438: Maladaptive decision-making is associated with psychological morbidity in people with Inflammatory Bowel Disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P438: Reinduction with ustekinumab in Crohn’s disease patients with a loss of response to treatment
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P438: The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P438: The inflammatory bowel disease disability index applied to ileal pouch anal anastomoses in New Zealand
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM